(Press-News.org) Results from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking improvement for patients who received chemotherapy before surgery to remove advanced squamous cell-type cancer of the nose or sinus. The European Society of Medical Oncology is highlighting the trial at its ESMO Congress 2024 in Barcelona, Spain. Surgery is required for these patients but at a high physical cost. Patients enrolled in this trial had signs that surgery would result in loss of the eye, the base of the skull bone, or both. However, in the randomized prospective trial EA3163, patients receiving chemotherapy before surgery had a 50% chance of structure preservation. In contrast, patients having surgery, the usual treatment, had only a 15% chance of preserving both the eye and the base of the skull bone. The National Cancer Institute, part of the National Institutes of Health, sponsored the study.
“These results support chemotherapy before surgery as an effective intervention to improve the preservation of vital organs, bone, and tissue in patients with nasal and paranasal sinus squamous cell carcinoma,” said lead investigator Nabil F. Saba. MD, Professor and Vice Chair, Lynne and Howard Halpern Chair in Head and Neck Cancer Research, Director of the Head and Neck Oncology Program at the Winship Cancer Institute, Emory University School of Medicine, and a member of the ECOG-ACRIN Head and Neck Cancer Committee.
Providing chemotherapy before surgery has shown questionable promise for improving organ preservation in small single-institution trials. Based on this suggestive data, some oncologists and surgeons recommend it for their patients. However, widespread adoption has been hampered by the lack of a randomized multi-center trial showing its advantages over primary surgery in terms of organ preservation. EA3163 was conducted to address this need.
“Because this disease is so rare, it was a bold move and significant undertaking to conduct this trial. Unlike the previously reported information on the role of chemotherapy in organ preservation, this study enrolled patients who were deemed to clearly need organ resection, and we tracked this information carefully, which allowed us to have a more objective examination as to the role of chemotherapy in organ preservation and be able to prove or disprove this approach. The EA3163 trial, therefore, provided the reliable platform to objectively compare the two approaches,” said Dr. Saba.
This prospective randomized clinical trial EA3163 (NCT03493425) aimed to enroll 82 patients with nasal and paranasal sinus squamous cell carcinoma, stage T3 and T4a (as well as select T4b). The trial enrolled 29 patients between March 2018 and August 2023 at multiple clinical sites in the United States. It closed in November 2023 after slow accrual. Results are being reported for 23 patients able to be evaluated.
“Despite being unable to complete the planned accrual and reach a definitive answer, the study results are striking and support the use of neoadjuvant chemotherapy as an intervention that could improve the chance of organ preservation for these patients. We are happy to see that structural preservation, in every possible way we examined it, favors neoadjuvant chemotherapy,” said Dr. Saba.
Nose and sinus cancer is a rare disease that affects about 2,000 people in the United States each year, mostly in people aged 55 and older (American Cancer Society). At presentation, patients typically have tumors in or near the eyes (orbit), the base of the skull bone, or both. The nasal cavity and paranasal sinus are close to many vital nerves, blood vessels, and other structures, making surgical planning and the surgery itself difficult. Thus, patients live with the debilitating effects of surgery and radiation for the rest of their lives.
Through study EA3163, Dr. Saba and colleagues aimed to reduce morbidity for these patients. They also hope to improve the current 5-year survival rate, which is below 50%. Participants continue to be monitored for 2-year overall survival.
“We believe future trials will need to test whether modifying the choice of chemotherapy or adding immunotherapy could improve the chance of organ preservation,” said senior investigator Barbara A. Burtness, MD, a Anthony N. Brady professor of medicine and Chief Translational Research Officer at Yale Cancer Center, chair of the ECOG-ACRIN Head and Neck Committee, and chair of the ECOG-ACRIN Task Force on Advancement for Women.
Patients in the control arm received surgery followed by radiation therapy (60 Gy). Patients in the experimental arm received three cycles of chemotherapy followed by surgery and radiation therapy (66 Gy). The chemotherapy consisted of docetaxel at 75 mg/m2 and cisplatin at 75 mg/m2. However, patients could receive carboplatin (40 mg/m2) instead of cisplatin if the treating physician deemed it necessary. These doses are considered very acceptable by National Comprehensive Cancer Network clinical practice guidelines.
Dr. Saba will present the results on Saturday, September 14, 2024, 8:30-10:00 AM CEST, in Barcelona. Abstract 850MO is posted on the ESMO Congress 2024 website. The title is: Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN Cancer Research Group (EA3163).
About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is an expansive membership-based scientific organization that designs and conducts research studies involving adults who have or are at risk of developing cancer. The Group comprises nearly 1400 member institutions and 21,000 research professionals in the United States and around the world. ECOG-ACRIN is known for advancing precision medicine and biomarker research through its leadership of major national clinical trials integrating cutting-edge genomic approaches. Its headquarters are in Philadelphia, PA, USA. Visit ecog-acrin.org, follow us on X @eaonc, as well as on Facebook, LinkedIn, Instagram, and YouTube, or call 215-789-3631.
END
Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
Striking results are seen from the only prospective multi-center randomized trial to examine chemotherapy before surgery to shrink tumors and reduce the amount of normal tissue that surgeons need to remove
2024-09-10
ELSE PRESS RELEASES FROM THIS DATE:
The glug of it all
2024-09-10
As Rohit Velankar, now a senior at Fox Chapel Area High School, poured juice into a glass, he could feel that the rhythmic glug, glug, glug was flexing the walls of the carton.
Rohit pondered the sound, and wondered if a container’s elasticity influenced the way its fluid drained. He initially sought the answer to his question for his science fair project, but it spiraled into something more when he teamed up with his father, Sachin Velankar, a professor of chemical and petroleum engineering at the University of Pittsburgh Swanson School of Engineering.
They set up an experiment ...
UTA to build netted drone facility in Fort Worth
2024-09-10
The University of Texas at Arlington is expanding its research and innovation capabilities by building a $2.3 million, state-of-the-art outdoor netted drone facility. The Maverick Autonomous Vehicle Research Center (MAVRC) will be located at the UT Arlington Research Institute (UTARI) in Fort Worth, with a planned completion date of January 2025.
“MAVRC will significantly and positively impact UTA’s presence in the region by supporting the university-industry-government-community ecosystem focused ...
Streamlining energy regulations on Native American reservations could help alleviate poverty
2024-09-10
MADISON–Land was once set aside as Native American reservations because it was undesirable and low in resources, but now interested Native Americans may have economic leverage in the growing industry of clean energy. A team of researchers led by UW–Madison professors Dominic Parker and Sarah Johnston quantified the economic potential of wind and solar energy projects on these lands and discussed the regulatory barriers for tribes wishing to tap into it.
“This is the first comprehensive ...
UT microbiologist Wilhelm honored as Fellow of the Royal Society of Canada
2024-09-10
Steven Wilhelm joins a distinguished roster this year with his election as a fellow of the Royal Society of Canada (RSC) Academy of Science. This recognition is the RSC’s highest honor in areas of arts, social sciences, humanities, and science.
“The RSC inducts fellows to help them build a better future in Canada and the world. As a native Canadian, this honor is the pinnacle of what I could have hoped for in my career,” said Wilhelm, the Kenneth and Blaire Mossman Professor in UT’s Department of Microbiology. “It also provides an opportunity for me to work with my collaborators ...
NCCN Policy Summit explores how to build an inclusive cancer center workplace culture that better serves everybody
2024-09-10
WASHINGTON, D.C. [September 10, 2024] — The National Comprehensive Cancer Network® (NCCN®) held an oncology policy summit today in Washington, D.C., focused on Advancing Diversity, Equity, and Inclusion in the Cancer Workforce. The event featured a keynote address from Tiffany Wallace, PhD, Branch Director, Disparities Research Branch, National Cancer Institute (NCI) Center for Cancer Health Equity. Panel discussions focused on how to establish and prioritize a culture of diversity, equity, inclusion, and belonging and maintain the commitment through a changing policy landscape. A series of ...
Games, puzzles and reading can slow cognitive decline in the elderly — even in those with mild cognitive impairment
2024-09-10
By Ann Kellett, Texas A&M University School of Public Health
The aging process can lead to diminished cognitive functioning for older adults. In addition, about 10 percent of people previously diagnosed with mild cognitive impairment develop Alzheimer’s disease or other forms of dementia every year.
Although a few studies have found that activities such as putting together jigsaw puzzles can protect against cognitive aging, the benefits of these activities in preventing or postponing cognitive ...
An antidiabetic helps the immune system recognize reservoirs of HIV
2024-09-10
Researchers at Université de Montréal’s affiliated hospital research centre, the CRCHUM, say the discovery could help lessen and even eliminate viral loads in people undergoing antiretroviral therapy.
Metformin, a drug used to treat type 2 diabetes, could help deplete the viral reservoir and eliminate it entirely in people living with HIV who receive antiretroviral therapy, Canadian researchers say in a new study.
In 2021, a team led by immunologist Petronela Ancuta of Université de Montréal’s affiliated hospital research centre, ...
Department of Energy grant advances clean energy studies
2024-09-10
Dr. Berna Hascakir, professor in the Harold Vance Department of Petroleum Engineering at Texas A&M University, was selected as part of a $17 million grant from the U.S. Department of Energy’s (DOE) Office of Fossil Energy and Carbon Management. The investment will support university-led projects that advance decarbonization and net-zero greenhouse gas emissions.
In partnership with Texas A&M, Texas Tech University, Howard University, and the University at Buffalo, this initiative unites three minority-serving ...
Finding the right path(way) to reduce fat accumulation in the liver
2024-09-10
Using a novel stem cell platform, a team of Medical University of South Carolina researchers has identified a pathway that could be targeted by drugs to reduce fat accumulation in patients with a common form of fatty liver disease known as metabolic dysfunction-associated steatotic liver disease, or MASLD. The MUSC team was led by Stephen Duncan, Ph.D., SmartState Endowed Chair in Regenerative Medicine at MUSC, and Caren Doueiry, an M.D., Ph.D. candidate in Duncan’s laboratory. The team reports its findings in the International Journal of Molecular Sciences.
Almost a quarter of Americans have MASLD, formerly known as non-alcoholic fatty liver disease. It ...
MicroDicer and MicroGrater make quick work of tumor dissection
2024-09-10
As fascinating as it is to work in a modern biology lab, in many cases a lot of repetitive, detailed work is necessary before the research can start. For example, cancer researchers are now capable of using hundreds or even thousands of small, lab-grown tumor samples – known as organoids – to test multiple cancer therapies, including immunotherapies, at once.
To produce organoids, researchers often need to mince a fresh tumor into small pieces by hand, using scissors to snip, snip, snip the specimen down to submillimeter size. This dissection work is tedious and yet often done by skilled – and usually overqualified ...
LAST 30 PRESS RELEASES:
SwRI-developed instruments will study potential habitability of Jupiter’s moon Europa
Proposed scoring system may enhance equity in organ transplantation, increase transplant rates and improve patient survival
Survivors of childhood brain cancer are more likely to be held back in school
Updating offshore turbine designs to reflect storms’ complexity is key
Hospital strain during the COVID-19 pandemic and outcomes in older racial and ethnic minority adults
Scientists unveils key role of “selfish DNA” in early human development
Bonobos may be more vulnerable than previously thought, suggests genetics study
Scripps Research scientists discover chemical probes for previously “undruggable” cancer target
Giant Magellan telescope begins primary mirror support system testing
Experimental cancer drug eliminates bone metastases caused by breast cancer in lab models
Political candidates who fight climate change stand to benefit in election
Stand up to Cancer announces new grants supporting pioneering research in six cancer types
Researchers awarded $1.3M to help military Veterans battling Acute Myeloid Leukemia
New hub for high-energy astrophysics — CTAO Science Data Management Centre opens at DESY in Zeuthen
JMIR publications CEO and Executive Editor Gunther Eysenbach achieves #1 ranking as most cited researcher in Medical Informatics for fifth consecutive year
ERC grant for groundbreaking wearable health tech
NIH announces winners of prize competition to improve postpartum maternal health and health equity through innovative diagnostics
APS and SPR honor Dr. Cynthia F. Bearer with the 2025 Mary Ellen Avery Neonatal Research Award
Election delays and voter trust
US air pollution monitoring network has gaps in coverage, say researchers
Continuous monitoring of fatigue in factory workers
Farmer ants’ wearable bacteria
Political polarization and trust
Study uncovers how silkworm moth's odor detection may improve robotics
New study links obesity to elevated hypertension risk among young middle eastern women
How ‘vaccinating’ plants could reduce pesticide use and secure global food supplies
Seven new frog species discovered in Madagascar: sounds like something from Star Trek
New temperatures in two thirds of key tropical forest
Fearful memories of others seen in mouse brain
Rangers lead ground-breaking effort to monitor Uganda's lion population in critical stronghold
[Press-News.org] Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removalStriking results are seen from the only prospective multi-center randomized trial to examine chemotherapy before surgery to shrink tumors and reduce the amount of normal tissue that surgeons need to remove